{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T09:35:37Z","timestamp":1768124137656,"version":"3.49.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T00:00:00Z","timestamp":1442188800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0138060","type":"journal-article","created":{"date-parts":[[2015,9,14]],"date-time":"2015-09-14T18:34:22Z","timestamp":1442255662000},"page":"e0138060","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy"],"prefix":"10.1371","volume":"10","author":[{"given":"Jun","family":"Itakura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masayuki","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayu","family":"Higuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natsuko","family":"Nakakuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshie","family":"Itakura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuharu","family":"Tamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoru","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuka","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Maekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Enomoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namiki","family":"Izumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,9,14]]},"reference":[{"issue":"9973","key":"ref1","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0140-6736(14)62401-6","article-title":"Hepatitis C","volume":"385","author":"DP Webster","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/17512433.2014.915737","article-title":"Antiviral therapy for chronic hepatitis C in 2014","volume":"7","author":"M Nookathota","year":"2014","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"C Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"issue":"5","key":"ref4","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"J-M Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"ref5","unstructured":"Recommendations on Treatment of Hepatitis C 2015. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/recommendations-on-treatment-of-hepatitis-c-2015\" xlink:type=\"simple\">http:\/\/www.easl.eu\/research\/our-contributions\/clinical-practice-guidelines\/detail\/recommendations-on-treatment-of-hepatitis-c-2015<\/ext-link>"},{"issue":"6","key":"ref6","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"H Kumada","year":"2014","journal-title":"Hepatology"},{"issue":"20","key":"ref7","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","article-title":"Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection","volume":"370","author":"N Afdhal","year":"2014","journal-title":"N Engl J Med"},{"issue":"21","key":"ref8","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1056\/NEJMoa1402338","article-title":"ABT-450\/r-ombitasvir and dasabuvir with or without ribavirin for HCV","volume":"370","author":"P Ferenci","year":"2014","journal-title":"N Engl J Med"},{"issue":"9973","key":"ref9","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(14)61793-1","article-title":"Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV\/hepatitis C virus co-infection (C-WORTHY): a rando","volume":"385","author":"M Sulkowski","year":"2014","journal-title":"Lancet"},{"issue":"2","key":"ref10","first-page":"375","article-title":"NS5A inhibitors in the treatment of hepatitis C","volume":"59","author":"J-M Pawlotsky","year":"2013","journal-title":"J Hepatol. European Association for the Study of the Liver"},{"issue":"11","key":"ref11","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.3748\/wjg.v20.i11.2902","article-title":"Hepatitis C virus NS5A inhibitors and drug resistance mutations","volume":"20","author":"S Nakamoto","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref12","first-page":"41","article-title":"Approaches to hepatitis C treatment and cure using NS5A inhibitors","volume":"7","author":"JJ Kohler","year":"2014","journal-title":"Infect Drug Resist"},{"key":"ref13","article-title":"Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to IL28B genotype and are sensitive to interferon-based therapy","volume":"6","author":"J Itakura","year":"2015","journal-title":"Hepatol Res"},{"issue":"9","key":"ref14","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1586\/14787210.2014.942282","article-title":"Efficacy of daclatasvir in hepatitis C virus","volume":"12","author":"N Izumi","year":"2014","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvh.12271","article-title":"Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1","volume":"22","author":"K Kosaka","year":"2015","journal-title":"J Viral Hepat"},{"key":"ref16","article-title":"Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy","volume":"8","author":"S Yoshimi","year":"2015","journal-title":"J Med Virol"},{"issue":"9954","key":"ref17","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","article-title":"All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study","volume":"384","author":"M Manns","year":"2014","journal-title":"Lancet"},{"issue":"14","key":"ref18","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","article-title":"Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection","volume":"44","author":"M Miura","year":"2014","journal-title":"Hepatol Res"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/hep.26788","article-title":"Hepatic interferon-stimulated genes are differentially regulated in the liver of chronic hepatitis C patients with different interleukin-28B genotypes","volume":"59","author":"M Honda","year":"2014","journal-title":"Hepatology"},{"issue":"5386","key":"ref20","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1126\/science.282.5386.103","article-title":"Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy","volume":"282","author":"AU Neumann","year":"1998","journal-title":"Science"},{"issue":"2","key":"ref21","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/clpt.2008.21","article-title":"Early and accurate prediction of Peg-IFNs\/ribavirin therapy outcome in the individual patient with chronic hepatitis C by modeling the dynamics of the infected cells","volume":"84","author":"P Colombatto","year":"2008","journal-title":"Clin Pharmacol Ther"},{"issue":"Suppl 1","key":"ref22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0168-8278(99)80374-2","article-title":"Molecular virology of the hepatitis C virus","volume":"31","author":"R De Francesco","year":"1999","journal-title":"J Hepatol"},{"issue":"24","key":"ref23","doi-asserted-by":"crossref","first-page":"12480","DOI":"10.1128\/JVI.01319-10","article-title":"Hepatitis C virus nonstructural protein 5A: biochemical characterization of a novel structural class of RNA-binding proteins","volume":"84","author":"J Hwang","year":"2010","journal-title":"J Virol"},{"issue":"36","key":"ref24","doi-asserted-by":"crossref","first-page":"30861","DOI":"10.1074\/jbc.M112.376822","article-title":"Correlation between NS5A dimerization and hepatitis C virus replication","volume":"287","author":"PJ Lim","year":"2012","journal-title":"J Biol Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1038\/srep04765","article-title":"Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA","volume":"4","author":"DB Ascher","year":"2014","journal-title":"Sci Rep"},{"issue":"6","key":"ref26","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1128\/JVI.02995-14","article-title":"Serine phosphorylation of the hepatitis C virus NS5A protein controls the establishment of replication complexes","volume":"89","author":"D Ross-Thriepland","year":"2014","journal-title":"J Virol"},{"issue":"5","key":"ref27","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1128\/AAC.04958-14","article-title":"Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories","volume":"59","author":"U Chatterji","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"ref28","doi-asserted-by":"crossref","first-page":"e1000035","DOI":"10.1371\/journal.ppat.1000035","article-title":"Essential role of domain III of nonstructural protein 5A for hepatitis C virus infectious particle assembly","volume":"4","author":"N Appel","year":"2008","journal-title":"PLoS Pathog"},{"issue":"2","key":"ref29","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1053\/j.gastro.2014.04.021","article-title":"Kinetic analyses reveal potent and early blockade of hepatitis C virus assembly by NS5A inhibitors","volume":"147","author":"DR McGivern","year":"2014","journal-title":"Gastroenterology"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1006\/viro.1997.8493","article-title":"Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein","volume":"230","author":"MJ Gale","year":"1997","journal-title":"Virology"},{"issue":"4","key":"ref31","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1128\/JVI.06577-11","article-title":"Hepatitis C virus proteins inhibit C3 complement production","volume":"86","author":"B Mazumdar","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1753425913478991","article-title":"Hepatitis C virus impairs TLR3 signaling and inhibits IFN-\u03bb 1 expression in human hepatoma cell line","volume":"20","author":"Y Wang","year":"2014","journal-title":"Innate Immun"},{"issue":"41","key":"ref33","doi-asserted-by":"crossref","first-page":"28343","DOI":"10.1074\/jbc.M109.038877","article-title":"The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo","volume":"284","author":"M Kriegs","year":"2009","journal-title":"J Biol Chem"},{"issue":"9","key":"ref34","doi-asserted-by":"crossref","first-page":"4395","DOI":"10.1128\/JVI.02352-08","article-title":"Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus","volume":"83","author":"RA Love","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/pro.2456","article-title":"The crystal structure of NS5A domain 1 from genotype 1a reveals new clues to the mechanism of action for dimeric HCV inhibitors","volume":"23","author":"SM Lambert","year":"2014","journal-title":"Protein Sci"},{"issue":"39","key":"ref36","doi-asserted-by":"crossref","first-page":"40835","DOI":"10.1074\/jbc.M404761200","article-title":"Structure and function of the membrane anchor domain of hepatitis C virus nonstructural protein 5A","volume":"279","author":"F Penin","year":"2004","journal-title":"J Biol Chem"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0138060","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T12:25:26Z","timestamp":1540038326000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0138060"}},"subtitle":[],"editor":[{"given":"Naoya","family":"Sakamoto","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,9,14]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2015,9,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0138060","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,14]]}}}